Shelly Wang, Ph.D. will be presenting a webinar for American Association of Pharmaceutical Scientists (AAPS).

This webinar aims to give an overview of the use of Model-informed Drug development (MIDD) in dose selection and optimization in oncology drug development from translating preclinical information to clinical development to determination of the dose for approval in general population and the dosing individualization for a specific patient.

Learning objectives:

1. Understand the need for oncology drug dose optimization
2. Appreciate the role of quantitative modeling in supporting dose optimization in oncology drug development
3. Discuss the Project Optimus initiative from the FDA and recommend holistic approach in the Optimization of dosing regimen for Oncology drug development
4. Review case studies involving the application of quantitative modelling in supporting oncology drug development